1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Australian Stock Exchange  -  05/23 12:17:02 am EDT
0.3200 AUD   -3.03%
04/28HEXIMA : ShareCafe Presentation
PU
04/27HEXIMA : Notification regarding unquoted securities - HXL
PU
04/04HEXIMA : Investor Webinar on Today
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Advisory Board

12/01/2021 | 04:49pm EDT

Hexima Limited announced the appointment of Shari Lipner, MD as a member of Hexima's Scientific Advisory Board. Dr. Lipner joins a high-profile advisory board comprising dermatologists and podiatrists based in Australia, the US and Japan. Dr. Lipner is an Associate Professor of Clinical Dermatology, Associate Attending Physician, and Director of the Nail Division at the New York-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Lipner has authored over two-hundred and fifty peer-reviewed publications, numerous book chapters, lectures nationally and internationally, and is a frequently sought out by the media for her expertise. She completed her undergraduate studies at Dartmouth College where she obtained a Bachelor of Arts in Chemistry and graduated Phi Beta Kappa and Summa Cum Laude.


© S&P Capital IQ 2021
All news about HEXIMA LIMITED
04/28HEXIMA : ShareCafe Presentation
PU
04/27HEXIMA : Notification regarding unquoted securities - HXL
PU
04/04HEXIMA : Investor Webinar on Today
PU
02/24HEXIMA : Application for quotation of securities - HXL
PU
02/23HEXIMA : Appendix 4D and Interim Financial Statements
PU
02/23Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2021
CI
02/08HEXIMA : Notification regarding unquoted securities - HXL
PU
01/31HEXIMA : Application for quotation of securities - HXL
PU
01/30HEXIMA : Quarterly Activities Report and Appendix 4C
PU
01/03Hexima Appoints Commercial Chief
MT
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,61 M -6,61 M
Net cash 2022 41,5 M 29,5 M 29,5 M
P/E ratio 2022 -5,49x
Yield 2022 -
Capitalization 53,5 M 38,0 M 38,0 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 47,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,32 AUD
Average target price 0,75 AUD
Spread / Average Target 134%
EPS Revisions
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-22.89%39
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567